胰高血糖素样肽1激动剂治疗后的哮喘相关初步结果。 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胰高血糖素样肽1激动剂治疗后的哮喘相关初步结果。 - Suppr | 超能文献

Preliminary asthma-related outcomes following glucagon-like peptide 1 agonist therapy.

作者信息

Khan F, Mat A, Hogan A E, Kent B D, Eigenheer S, Corrigan M A, O'Shea D, Butler M W

机构信息

From the Respiratory Department, Clinical Research Centre, St Vincent's University Hospital, Dublin, Ireland.

Respiratory Department, University College Dublin, Dublin, Ireland.

出版信息

QJM. 2017 Dec 1;110(12):853-854. doi: 10.1093/qjmed/hcx125.

DOI:10.1093/qjmed/hcx125

Abstract

摘要

相似文献

1

Preliminary asthma-related outcomes following glucagon-like peptide 1 agonist therapy.胰高血糖素样肽1激动剂治疗后的哮喘相关初步结果。

QJM. 2017 Dec 1;110(12):853-854. doi: 10.1093/qjmed/hcx125.

2

No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.GLP-1 受体激动剂治疗后无胰腺安全性担忧：心血管结局试验的汇总分析。

Diabetes Metab Res Rev. 2018 Nov;34(8):e3061. doi: 10.1002/dmrr.3061. Epub 2018 Sep 14.

3

Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?司美格鲁肽用于2型糖尿病——它是最佳的胰高血糖素样肽1受体激动剂（GLP-1R激动剂）吗？

Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):371-377. doi: 10.1080/17425255.2018.1441286. Epub 2018 Feb 23.

4

Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.胰高血糖素样肽-1 受体介导的心脏能量代谢调控。

Peptides. 2018 Feb;100:94-100. doi: 10.1016/j.peptides.2017.12.005.

5

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.胃泌酸调节素和胰高血糖素样肽-1对小鼠食物摄入量和能量消耗的调节作用存在差异。

Gastroenterology. 2004 Aug;127(2):546-58. doi: 10.1053/j.gastro.2004.04.063.

6

Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.具有延长的胰高血糖素样肽-1受体激动剂和胰高血糖素受体拮抗剂活性的双功能肽，用于治疗2型糖尿病。

J Endocrinol. 2007 Feb;192(2):371-80. doi: 10.1677/JOE-06-0018.

7

Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.胰高血糖素样肽-1（GLP-1）通过蛋白激酶A（PKA）依赖性核因子-κB（NF-κB）信号通路调节卵清蛋白诱导的小鼠气道炎症和黏液分泌。

Int J Mol Sci. 2015 Aug 26;16(9):20195-211. doi: 10.3390/ijms160920195.

8

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.用于治疗2型糖尿病的胰高血糖素样肽-1激动剂的药物遗传学

Curr Clin Pharmacol. 2017;12(4):202-209. doi: 10.2174/1574884713666180221121512.

9

Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes.3T3-L1脂肪细胞中胰高血糖素样肽受体的新型信号转导及肽特异性

J Cell Physiol. 1997 Sep;172(3):275-83. doi: 10.1002/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L.

10

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病患者体重减轻的影响：一项系统评价与混合治疗比较的Meta分析

PLoS One. 2015 Jun 29;10(6):e0126769. doi: 10.1371/journal.pone.0126769. eCollection 2015.

引用本文的文献

1

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?胰高血糖素样肽-1（GLP-1）及胃抑肽/胰高血糖素样肽-1（GIP/GLP-1）受体激动剂在呼吸系统疾病中的潜在应用：我们目前进展如何？

Medicina (Kaunas). 2024 Dec 9;60(12):2030. doi: 10.3390/medicina60122030.

2

The role of type 2 diabetes in the severity of adult asthma.2型糖尿病在成人哮喘严重程度中的作用。

Curr Opin Allergy Clin Immunol. 2025 Feb 1;25(1):34-40. doi: 10.1097/ACI.0000000000001045. Epub 2024 Nov 20.

3

Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches.

肥胖相关性哮喘：基于病理生理学的现有和新兴治疗方法概述。

Am J Respir Crit Care Med. 2024 Nov 15;210(10):1186-1200. doi: 10.1164/rccm.202406-1166SO.

4

Association of Obesity and Severe Asthma in Adults.成人肥胖与重度哮喘的关联

J Clin Med. 2024 Jun 14;13(12):3474. doi: 10.3390/jcm13123474.

5

The Role of Peptides in Asthma-Obesity Phenotype.肽在哮喘-肥胖表型中的作用。

Int J Mol Sci. 2024 Mar 12;25(6):3213. doi: 10.3390/ijms25063213.

6

Unraveling the Link between Ιnsulin Resistance and Bronchial Asthma.揭示胰岛素抵抗与支气管哮喘之间的联系。

Biomedicines. 2024 Feb 16;12(2):437. doi: 10.3390/biomedicines12020437.

7

Management of the pediatric patient with asthma and obesity.小儿哮喘合并肥胖患者的管理。

Ann Allergy Asthma Immunol. 2024 Jan;132(1):30-39. doi: 10.1016/j.anai.2023.10.001. Epub 2023 Oct 10.

8

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity.降血糖药物治疗合并肥胖哮喘的效用

Pulm Ther. 2023 Mar;9(1):71-89. doi: 10.1007/s41030-022-00211-x. Epub 2022 Dec 27.

9

The Interaction of Food Allergy and Diabetes: Food Allergy Effects on Diabetic Mice by Intestinal Barrier Destruction and Glucagon-like Peptide 1 Reduction in Jejunum.食物过敏与糖尿病的相互作用：食物过敏通过破坏肠道屏障和降低空肠中胰高血糖素样肽1对糖尿病小鼠产生的影响。

Foods. 2022 Nov 22;11(23):3758. doi: 10.3390/foods11233758.

10

Beneficial Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Asthma: A Literature Review.胰高血糖素样肽-1受体激动剂对哮喘患者的有益作用：文献综述

Cureus. 2022 Oct 28;14(10):e30812. doi: 10.7759/cureus.30812. eCollection 2022 Oct.